Suppr超能文献

6,9-二芳基嘌呤-8-酮作为p38丝裂原活化蛋白激酶抑制剂的合成、生物学测试及结合模式预测

Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitors.

作者信息

Hauser Dominik R J, Scior Thomas, Domeyer David M, Kammerer Bernd, Laufer Stefan A

机构信息

Department of Pharmaceutical and Medicinal Chemistry, Eberhard-Karls-University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany.

出版信息

J Med Chem. 2007 May 3;50(9):2060-6. doi: 10.1021/jm061061w. Epub 2007 Apr 6.

Abstract

Based on the purine scaffold of ATP, derivatives of 6,9-diarylpurine-8-one were prepared and tested for their ability to inhibit p38 MAP kinase, a key enzyme in the cellular regulation of proinflammatory cytokines. The inhibitor design combines the purine system of the authentic cosubstrate ATP with various phenyl moieties to explore the selectivity for the two hydrophobic regions of the kinase's ATP-binding cleft. The present study indicates a new binding mode of our scaffold to p38 MAP kinase, which comprises the desired structural features of ATP and the N-phenyl-N-purin-6-yl ureas previously published by Wan et al. Combinations of Autodock and FlexX docking with different scoring functions were used to assess the postulated binding mode. The predictive power of different docking-scoring combinations was determined. The presented results may form a solid basis for further optimization cycles since our theoretical findings are consistent with our experimental binding data and supported by the literature.

摘要

基于ATP的嘌呤骨架,制备了6,9-二芳基嘌呤-8-酮衍生物,并测试了它们抑制p38丝裂原活化蛋白激酶的能力,p38丝裂原活化蛋白激酶是细胞调节促炎细胞因子的关键酶。抑制剂设计将真实共底物ATP的嘌呤系统与各种苯基部分结合起来,以探索激酶ATP结合裂隙两个疏水区域的选择性。本研究表明我们的骨架与p38丝裂原活化蛋白激酶的一种新结合模式,该模式包含ATP以及Wan等人先前发表的N-苯基-N-嘌呤-6-基脲的所需结构特征。使用结合不同评分函数的自动对接和FlexX对接组合来评估假定的结合模式。确定了不同对接评分组合的预测能力。由于我们的理论发现与实验结合数据一致并得到文献支持,所呈现的结果可能为进一步的优化循环奠定坚实基础。

相似文献

1
Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitors.
J Med Chem. 2007 May 3;50(9):2060-6. doi: 10.1021/jm061061w. Epub 2007 Apr 6.
6
Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.
Bioorg Med Chem Lett. 2008 Jun 1;18(11):3251-5. doi: 10.1016/j.bmcl.2008.04.043. Epub 2008 Apr 25.
7
Tagged fragment method for evolutionary structure-based de novo lead generation and optimization.
J Med Chem. 2007 Nov 1;50(22):5392-402. doi: 10.1021/jm070750k. Epub 2007 Oct 6.
9
The three-dimensional structure of MAP kinase p38beta: different features of the ATP-binding site in p38beta compared with p38alpha.
Acta Crystallogr D Biol Crystallogr. 2009 Aug;65(Pt 8):777-85. doi: 10.1107/S090744490901600X. Epub 2009 Jul 10.
10
The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Bioorg Med Chem Lett. 2008 Mar 15;18(6):1772-7. doi: 10.1016/j.bmcl.2008.02.033. Epub 2008 Feb 16.

引用本文的文献

1
Medicinal chemistry perspective of pyrido[2,3-]pyrimidines as anticancer agents.
RSC Adv. 2023 Feb 28;13(10):6872-6908. doi: 10.1039/d3ra00056g. eCollection 2023 Feb 21.
2
Sustainable synthesis and automated deposition: an accessible discovery screening library of fragment-like purines.
Mol Divers. 2012 Aug;16(3):541-51. doi: 10.1007/s11030-012-9386-x. Epub 2012 Aug 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验